Fresenius Kabi adds lacosamide injection to its product portfolio. The lacosamide injection, USP is supplied in a 200 mg per 20 mL single-dose vial presentation for intravenous (IV) use.
Fresenius Kabi USA For more information, visit pppmag.com/info
www.pppmag.com uses tracking technologies. The site may also
include cookies from third parties. By continuing to use this website, you consent
to the use of tracking technologies as defined in our
Privacy Policy that can be read by clicking here.